Adding Idasanutlin to Cytarabine Does Not Improve OS in Relapsed/Refractory AML
Researchers sought to determine whether adding idasanutlin to cytarabine would improve OS in patients with relapsed or refractory acute myeloid leukemia.
All articles by Jonathan Goodman, MPhil
Gene Expression Profiling Could Inform Treatment of Non-Clear Cell Renal Cell Carcinoma
Nearly half of non-clear cell renal cell carcinoma samples were classified as proliferative.
Study Reveals Shorter Time to Lung Cancer Treatment During COVID-19 Pandemic
The time from cytohistological diagnosis to treatment initiation was longer in 2019 than in 2020.
Type of Surgery and Surgical Pathway Tied to Risk of Perioperative COVID-19 in Non-Small Cell Lung Cancer
Perioperative COVID-19 was associated with a 30-day mortality rate of 26%.
How to Prevent COVID-19 Vaccination From Interfering With Cancer Imaging
Education, communication, and coordination are key.
Epigenetic Analysis Outlines Factors Predicting HMA Response in MDS, AML
Researchers sought to determine what factors may help predict what patients with MDS or AML would respond to treatment with azacitidine.
Patients With Multiple Myeloma Receiving Belantamab Mafodotin Can Recover From Ocular Events
Researchers sought to determine whether patients with RRMM with ocular events induced by belantamab mafodotin would recover without discontinuing treatment.
HFE Mutations Have Unknown Impact on Outcomes for Patients With Myelodysplastic Syndromes
Researchers evaluated the rates and significance of HFE variants in a population of patients with MDS.
Whole-Genome Sequencing Shows Promise for Risk Stratification in AML, MDS
Researchers sought to determine whether whole-genome sequencing may be a better risk stratification tool compared with conventional cytogenetic analysis.
Hypomagnesemia at Time of Transplant Associated With Worse Survival in Patients With DLBCL
Researchers sought to determine whether hypomagnesemia increases the risk of failure for autologous hematopoietic stem cell transplantation in patients with DLBCL.
- Loading...
Loading...
Next post in Lymphoma
Loading... 
Loading...